BrainVectis

Developing gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain.

Launch date

Jul 2015

Employees

Market cap

Enterprise valuation

Company register number 813073517

Paris Île-de-France (HQ)

http://www.brainvectis.com/

https://twitter.com/brain_vectis https://www.linkedin.com/company/brainvectis/

Revenues, earnings & profits over time

EUR	2018	2019	2020	2021	2022
Revenues	-	-	<1m	3.8m	7.5m
% growth	-	-	-	181934 %	96 %
EBITDA	-	(1.3m)	(1.6m)	<1m	<1m
% EBITDA margin	-	-	(77009 %)	9 %	8 %
Profit	(<1m)	(<1m)	(<1m)	<1m	1.2m
% profit margin	-	-	(46990 %)	20 %	17 %

Date	Investors	Amount	Round
-	Erganeo	N/A	-
Sep 2016*	N/A	€1.0m	Series A
Apr 2020*	AskBio	N/A	Acquisition
Total Funding		$1.1m

Tech stackLearn more about the technologies and tools that this company uses.